IL1B and myocardial infarction: Therefore, in vivo studies investigating the inhibition of IL-1β in experimental models of MI using targeted anti-inflammatory interventions have resulted in reduced adverse remodeling and progression to heart failure (HF) [8,9,10,11], which have led to human clinical trials showing promising results in patients with MI [12,13,14].